Why Entera Bio Ltd.’s (ENTX) Stock Is Up 10.73%
As of Wednesday, August 19, Entera Bio Ltd.’s ENTX share price has surged by 10.73%, which has investors questioning if this is right time to sell.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Entera Bio Ltd., a clinical stage company, engages in the development of oral peptides and protein replacement therapies in Israel and internationally. It develops EB613, an oral teriparatide, which completed the Phase II clinical trial for the treatment of osteoporosis and Phase I clinical trial for the treatment of stress fractures. The company is also involved in the development of EB612, a tablet peptide replacement therapy, which is in Phase I clinical trial for the treatment of hypoparathyroidism; EB618, a GLP-1/glucagon dual agonist peptide, which is in Phase I clinical trial for the treatment of obesity, metabolic, and fibrotic disorders; and GLP-2 which is in Phase I clinical trial for the treatment of short bowel syndrome and disorders related to mucosal inflammation and nutrient malabsorption. It has a collaboration agreement with OPKO Biologics, Inc for the preclinical and clinical development of LA-PTH and oral dual agonist GLP-1/glucagon peptide. The company was incorporated in 2009 and is based in Jerusalem, Israel.
Commentary & Analysis
Why Entera Bio Ltd.’s (ENTX) Stock Is Down 5.67%
As of Wednesday, August 12, Entera Bio Ltd.’s ENTX share price has dipped by 5.67%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Entera Bio Ltd.’s (ENTX) Stock Is Down 7.57%
As of Tuesday, August 11, Entera Bio Ltd.’s ENTX share price has dipped by 7.57%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Entera Bio Ltd.’s (ENTX) Stock Is Down 5.57%
As of Monday, August 10, Entera Bio Ltd.’s ENTX share price has dipped by 5.57%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Entera Bio Ltd.’s (ENTX) Stock Is Down 6.42%
As of Tuesday, August 04, Entera Bio Ltd.’s ENTX share price has dipped by 6.42%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Financial Summary
| Share Statistics | ENTX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $559.2 | $286.3 | 38% |
|
| Shares Out (Mil) | 50.5 | 54.2 | 48% |
|
| Institutional Ownership | 94.4% | 92.8% | 65% |
|
| Float (Mil) | 121.5 | 39.7 | 65% |
|
| Beta | 1.40 | 0.94 | 80% |
|
| Avg Daily Volume (000s) | 412 | 534 | 55% |
|
| Price Change (52-week) |
70.9% | 58.7% | 86% |
|
| Growth | ENTX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | (0.4%) | (10.1%) | 39% |
|
| EPS (5yr) | 16.4% | 16.0% | 60 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | 19.0% | (15.6%) | 78% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | ENTX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($17) | ($43) | 25% |
|
| EPS (TTM) | ($0.354) | ($1.400) | 30% |
|
| Operating Cash Flow (TTM) (Mil) | ($11) | ($31) | 19% |
|
| Net Cash Flow (TTM) (Mil) | na | $2 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 12% |
|
| Enterprise Value (Q1) (Mil) | $516 | $160 | 34% |
|
| Valuation | ENTX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 21.53 | 2.77 | 96% |
|
| P/E | na | 19.1 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | ENTX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 64.2% | na |
|
| Net Margin | na | (75.9%) | na |
|
| ROA | (87.0%) | (47.3%) | 6% |
|
| ROE | (138.9%) | (55.0%) | 6% |
|
| Liabilities to Assets | 62.7% | 29.6% | 57% |
|
| F-Score | 1 | 2 | 1% |
|
Passing Stock Screens
As of 8/20/2026, from a list of 60 stock screening strategies,
FACTOR STRATEGY
Insider Net Purchases Screen
Factors: Other
A stock screen designed to find small-cap companies that have more stock purchased than sold by insiders.
| Performance Since Inception: | -2.4% |
| +/- S&P 500: | -9.9 |
